Evidence map›Paper›PMID 38255684›Full record

ReviewLife (Basel, Switzerland)2023

Neurosarcoidosis: The Presentation, Diagnosis and Treatment Review of Two Cases.

Maamoun Basheer, Hamd Waked, Helana Jeries, Olga Azrilin, Dan Paz, Nimer Assy, Mohammad E Naffaa, Samih Badarny

Open access · goldAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Maamoun BasheerInternal Medicine Department, Galilee Medical Center, Nahariya 221001, Israel.
Hamd WakedNeurology Department, Galilee Medical Center, Nahariya 221001, Israel.
Helana JeriesRheumatology Unit, Galilee Medical Center, Nahariya 221001, Israel.ORCID 0000-0001-8624-6332
Olga AzrilinNeurology Department, Galilee Medical Center, Nahariya 221001, Israel.
Dan PazRadiology Department, Galilee Medical Center, Nahariya 221001, Israel.
Nimer AssyInternal Medicine Department, Galilee Medical Center, Nahariya 221001, Israel.ORCID 0000-0002-2279-6041
Mohammad E NaffaaRadiology Department, Galilee Medical Center, Nahariya 221001, Israel.ORCID 0000-0001-9777-2864
Samih BadarnyNeurology Department, Galilee Medical Center, Nahariya 221001, Israel.ORCID 0000-0003-3305-6054
Western Galilee Hospital · ILBar-Ilan University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sarcoidosis is a chronic granulomatous disease of unknown cause characterized by the presence of non-caseating granulomas. The disease can affect any organ including the nervous system. Neurosarcoidosis occurs in about 5% patients with sarcoidosis. The clinical presentation of neurosarcoidosis is varied, and it can involve the brain, spinal cord and peripheral nervous system, separately or in different combinations. The diagnosis of neurosarcoidosis is challenging, as biopsies from the nervous system are not readily available. Anti-TNFα agents are becoming one of the cornerstone treatments for neurosarcoidosis. In this case-based review, we discuss two cases of neurosarcoidosis with different clinical presentations. The first patient presented with confusion, while the second presented with walking difficulty and neurogenic bladder. Both patients were treated with methylprednisolone pulse therapy with rapid, but non-complete, improvement. Therefore, infliximab was initiated in both cases with subsequent improvement in the clinical manifestations and imaging findings, emphasizing the effectiveness and safety of infliximab in cases of severe neurosarcoidosis. In conclusion, the goal of neurosarcoidosis management is to prevent organ system damage and minimize the toxic cumulative adverse effects of glucocorticoid use. In this case-based review we discuss the various presentations, the diagnosis and the treatment of neurosarcoidosis.

Indexed as

anti-TNFα agentseffectivenessinfliximabnervous systemneurosarcoidosissafety

Identifiers

PMID38255684
PMCPMC10820900
OpenAlexW4390467165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.